Skip to main content
SpringerLink
Log in

Melanom: Antikörper verdoppelt Überlebenschance

  • Literatur kompakt
  • Published:
hautnah dermatologie Aims and scope

Die Einführung des Antikörpers Ipilimumab zur Therapie bei Hautkrebs vor vier Jahren wurde als Durchbruch gefeiert. Langzeitdaten zeigen jetzt: Es wurde nicht zu viel versprochen.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  • Maio et al. Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. J Clin Oncol 2015; 33: 1191–6

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. http://www.springermedizin.de

    Thomas Müller

Authors
  1. Thomas Müller
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Müller, T. Melanom: Antikörper verdoppelt Überlebenschance. hautnah dermatologie 31, 26 (2015). https://doi.org/10.1007/s15012-015-1832-x

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15012-015-1832-x

Search

Navigation